10 References to Not Test Your Integrity

1. FTC Report: Pharmacy Benefit Managers—The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies

   Supports the discussion of reimbursement pressure, PBM practices, pharmacy financial viability, and independent-pharmacy closures.

2. 2024 NCPA Digest

   Documents declining independent-pharmacy profitability, below-cost reimbursements, rising expenses, and historically low gross margins.

3. CMS Fraud Prevention System 2.0

   Confirms that CMS uses predictive analytics to detect troublesome billing patterns, outlier claims, and potentially fraudulent activity.

4. GAO: Medicare’s Use of Data Analytics to Identify and Prevent Fraud

   Explains how CMS and private payers analyze billing spikes and other anomalous provider patterns. GAO reports that CMS estimated preventing approximately $11.9 billion in potentially fraudulent payments during fiscal years 2022–2024.

5. IRS Policy for Artificial Intelligence Governance

   Confirms the IRS’s formal use and governance of artificial intelligence. This supports the comparison with technology-assisted tax compliance and enforcement.

6. HHS-OIG: Reducing Pharmacy Fraud in Medicare Part D

   Describes OIG’s examination of whether pharmacies identified as bad actors continue billing and receiving Medicare Part D payments.

7. DOJ: Five New Jersey Pharmacies Resolve Billing Allegations

   Provides examples of pharmacies accused of billing Medicare Part D and Medicaid for medications that were never dispensed.

8. DOJ: Four Hudson County Pharmacies Pay $4.3 Million

   Provides additional recent examples of claims allegedly submitted for medications never dispensed.

9. DOJ: Worcester Pharmacy Resolves Claims Unsupported by Inventory

   Directly supports the warning that investigators can compare billed prescriptions with purchasing and inventory records.

10. DOJ: Pharmacy Owner Sentenced for Healthcare Fraud

    Supports the discussion of billing for medications not dispensed, failing to reverse claims for returned drugs, and dispensing and billing returned medication again.

For the stock-purchase discussion, this additional reference is useful: Pharmacy Mergers and Acquisitions—Stock Versus Asset Purchases. It explains that stock purchases can provide greater entity continuity but also expose buyers to existing and contingent liabilities. Because actual treatment varies by contract, program, and state, the applicable PBM agreements and change-of-ownership rules must be reviewed for each transaction.